Bioptik Technology
Bioptik Technology Incorporation engages in the manufacturing, wholesale, and retail of biotechnology and medical equipment in Taiwan and internationally. It offers blood glucose, cholesterol, uric acid, hemoglobin and acid multi-function monitoring systems under the EasyMate, EasySure, and EasyTouch brand name, as well as PeTouch Glucose Monitoring System for Dogs and Cats. The company also prov… Read more
Bioptik Technology (4161) - Total Liabilities
Latest total liabilities as of September 2025: NT$515.33 Million TWD
Based on the latest financial reports, Bioptik Technology (4161) has total liabilities worth NT$515.33 Million TWD as of September 2025.
Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Bioptik Technology - Total Liabilities Trend (2017–2024)
This chart illustrates how Bioptik Technology's total liabilities have evolved over time, based on quarterly financial data. Explore and compare other companies by total liabilities.
Bioptik Technology Competitors by Total Liabilities
The table below lists competitors of Bioptik Technology ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
S Prime Growth Leasehold Real Estate Investment Trust
BK:SPRIME
|
Thailand | ฿1.50 Billion |
|
Ribbon Acquisition Corp Class A Ordinary Shares
NASDAQ:RIBB
|
USA | $2.31 Million |
|
Zedge Inc
NYSE MKT:ZDGE
|
USA | $9.75 Million |
|
Bali Bintang Sejahtera Tbk PT
JK:BOLA
|
Indonesia | Rp129.33 Billion |
|
Alaska Silver Corp.
F:MK7
|
Germany | €6.35 Million |
|
Silver X Mining Corp
OTCQB:AGXPF
|
USA | $37.63 Million |
|
SEC
KQ:081180
|
Korea | ₩60.91 Billion |
|
Reviva Pharmaceuticals Holdings Inc.
NASDAQ:RVPH
|
USA | $9.78 Million |
Liability Composition Analysis (2017–2024)
This chart breaks down Bioptik Technology's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 2.06 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.55 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.35 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Bioptik Technology's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Bioptik Technology (2017–2024)
The table below shows the annual total liabilities of Bioptik Technology from 2017 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | NT$582.47 Million | -13.52% |
| 2023-12-31 | NT$673.56 Million | -15.53% |
| 2022-12-31 | NT$797.40 Million | -3.86% |
| 2021-12-31 | NT$829.38 Million | +12.37% |
| 2020-12-31 | NT$738.10 Million | -6.10% |
| 2019-12-31 | NT$786.05 Million | -0.76% |
| 2018-12-31 | NT$792.07 Million | +16.81% |
| 2017-12-31 | NT$678.08 Million | -- |